Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE The CD4 count was associated with PFS irrespective of IGHV mutational status, but only in patients with detectable MRD (HR, 3.51, p = 0.0004, whereas it had no prognostic impact in MRD < 10<sup>- 4</sup> patients: p = 0.6998). 31412798 2019
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE In 16 QC rounds between 2010 and 2017, the four laboratories received 208 bone marrow (BM) samples (126 FL; 82 MCL); 187 were analyzed, according to the EuroMRD Consortium guidelines, by both nested (NEST) polymerase chain reaction (PCR) and real-time quantitative (RQ) PCR for BCL2/IGH MBR or IGHV rearrangements. 31325190 2019
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE This chapter provides all relevant background information and technical aspects for the complete laboratory process from detection of the clonal IGHV gene rearrangement and the chromosomal translocations at diagnosis to the actual MRD measurements in clinical follow-up samples of B-NHL. 30779036 2019
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE A distinct MRD high-risk subgroup of IGH-V(D)J-germline ALL revealed frequent deletions of IKZF1 (n = 7/11) and the presence of genomic fusions (n = 10/11). 31784504 2019
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 AlteredExpression phenotype BEFREE We have measured MRD level in follow-up samples from 27 patients diagnosed with MCL using the molecular markers: t(11;14), IGH rearrangement and SOX11 expression. 29520657 2018
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE We identified 14 of 17 IGH translocations previously detected by FISH and three confirmed translocations not detected by FISH, with the additional advantage of breakpoint identification, which can be used as a target for evaluating minimal residual disease. 27863261 2017
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE The aim of this study was to use clonal IGH/IGK-Kde gene rearrangements to confirm B-ALL diagnosis and to evaluate the treatment outcome of Tunisian leukemic patients by monitoring the minimal residual disease (MRD) after induction chemotherapy. 28099581 2017
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE PB is a suitable source for serial BCL2/IGH MRD assessments, regardless of the methodology utilized. 28419517 2017
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE 50.7% of patients with IGHV-M achieved MRD-negativity posttreatment; of these, PFS was 79.8% at 12.8 years. 26492934 2016
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE Furthermore, there was a strong correlation (r = 0.94) between flow cytometric and RQ-ASO IGH PCR results in MRD detection. 24028768 2014
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE Deep sequencing was carried out in patients in whom a high-frequency myeloma clone was identified and MRD was assessed using the IGH-VDJH, IGH-DJH, and IGK assays. 24646471 2014
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). 24700492 2014
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE In this study we aimed to assess the value of real-time polymerase chain reaction (RT-PCR) for detecting the immunoglobulin heavy chain (IgH) gene rearrangement using allele-specific molecular beacons as fluorescence probes to quantify minimal residual disease (MRD) and also to correlate post-treatment flow cytometric detection of plasma cells' (PCs) expression of CD19, CD38, CD45, CD56 and CD138 in MM. 23818359 2013
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE This chapter provides all relevant background information and technical aspects for the complete laboratory process from detection of the clonal IgH gene rearrangement and the chromosomal translocations at diagnosis to the actual MRD measurements in clinical follow-up samples of B-NHL. 23296964 2013
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. 22368272 2012
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE Plasmid-based standards for the quantification of IGH VDJ targets are therefore confirmed to offer new opportunities for further standardization and clinical evaluation of MRD-guided management of patients with mature B cell malignancies. 22626453 2012
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE Here we describe a method for quantifying CLL MRD using widely available consensus primers for amplification of all Ig heavy chain (IGH) genes in a mixture of peripheral blood mononuclear cells, followed by high-throughput sequencing (HTS) for disease-specific IGH sequence quantification. 22160699 2011
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE This is because the issue of the benefits of achieving MRD-negative status in patients with CLL requires further investigation in large controlled trials, in which patients should be stratified according to not only clinical variables but also biological parameters such as cytogenetics, IGHV mutations or ZAP-70 expression. 20620974 2010
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE Oligoclonal IGH rearrangements, on the other hand, may be instable at relapse and should therefore not be used for minimal residual disease analysis. 19148138 2009
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. 19641522 2009
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. 19324994 2009
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma. 16825510 2006
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 Biomarker phenotype BEFREE Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. 16197448 2005
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE We evaluate whether molecular monitoring of minimal residual disease (MRD) using TCR delta (TCRD), TCR gamma (TCRG), and immunoglobulin H (IgH) gene rearrangements in the bone marrow (BM) is correlated with clinical events in ALL patients. 16247752 2005
Entrez Id: 3492
Gene Symbol: IGH
IGH
0.100 GeneticVariation phenotype BEFREE MGB technology is useful for the design of consensus fluorogenically labeled probes of the IgH gene for detecting MRD. 15034598 2004